Curis Inc (CRIS) - Total Liabilities
Based on the latest financial reports, Curis Inc (CRIS) has total liabilities worth $16.98 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Curis Inc (CRIS) investment intensity to see how much of total assets are deployed in long-term investments.
Curis Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Curis Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Curis Inc total assets.
Curis Inc Competitors by Total Liabilities
The table below lists competitors of Curis Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GIVOT OLAM OIL EXP ILS1
TA:GIVO-L
|
Israel | ILA25.35 Million |
|
Vistal Gdynia
WAR:VTL
|
Poland | zł565.15 Million |
|
Hansa Trust
LSE:HAN
|
UK | GBX46.84 Million |
|
Abrdn UK Smaller Companies Growth Trust PLC
LSE:AUSC
|
UK | GBX42.25 Million |
|
Conduit Pharmaceuticals Inc.
NASDAQ:CDT
|
USA | $2.12 Billion |
|
Transition Evergreen
PA:EGR
|
France | €56.53 Million |
|
FAT Brands Inc
NASDAQ:FAT
|
USA | $1.80 Billion |
|
Riwi Corp
V:RIWI
|
Canada | CA$2.46 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Curis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CRIS net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Curis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Curis Inc (1999–2025)
The table below shows the annual total liabilities of Curis Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.50 Million | -69.31% |
| 2024-12-31 | $47.26 Million | -17.96% |
| 2023-12-31 | $57.61 Million | -7.52% |
| 2022-12-31 | $62.30 Million | -12.99% |
| 2021-12-31 | $71.59 Million | -2.84% |
| 2020-12-31 | $73.69 Million | +6.77% |
| 2019-12-31 | $69.02 Million | +64.87% |
| 2018-12-31 | $41.86 Million | -15.95% |
| 2017-12-31 | $49.80 Million | +74.84% |
| 2016-12-31 | $28.49 Million | -6.46% |
| 2015-12-31 | $30.45 Million | -7.24% |
| 2014-12-31 | $32.83 Million | -7.31% |
| 2013-12-31 | $35.42 Million | -0.83% |
| 2012-12-31 | $35.71 Million | +330.06% |
| 2011-12-31 | $8.30 Million | +61.83% |
| 2010-12-31 | $5.13 Million | +68.41% |
| 2009-12-31 | $3.05 Million | +10.51% |
| 2008-12-31 | $2.76 Million | -60.45% |
| 2007-12-31 | $6.97 Million | -57.41% |
| 2006-12-31 | $16.37 Million | -28.56% |
| 2005-12-31 | $22.91 Million | +22.37% |
| 2004-12-31 | $18.73 Million | +10.99% |
| 2003-12-31 | $16.87 Million | -61.57% |
| 2002-12-31 | $43.90 Million | +0.37% |
| 2001-12-31 | $43.74 Million | +215.37% |
| 2000-12-31 | $13.87 Million | +153.50% |
| 1999-12-31 | $5.47 Million | -- |
About Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. … Read more